Precision Immune Monitoring in Cell Therapy

Explore how Dextramer® reagents support the development and manufacturing of effective cell therapies.

Monitor Antigen Specificity

Specificity can be key to successful immune cell therapy. Immudex provides high-quality Dextramer® reagents that enable precision cellular immune monitoring of antigen-specific cells for advanced cell therapy.

Reagents for Development and Manufacturing

Immudex is committed to providing sensitive Dextramer® reagents for precise detection, isolation, and validation of antigen-specific cells in cell therapy development and manufacturing.

Clinical Grade Reagents

Immudex provides high-quality GMP Dextramer® reagents that meet authoritative standards for production and manufacturing of cell therapy products.

Specificity can be Key to Successful Immune Cell Therapy

Immudex provides high-quality Dextramer® reagents that enable precision cellular immune monitoring of antigen-specific cells.

Dextramer® technology can characterize and validate antigen-specific cell therapy products with high resolution during development, manufacturing, and release testing.

Develop and Manufacture Cell Therapies with Dextramer® Technology 

Explore Case Studies – Applications of Dextramer® Technology in Cell Therapy

Screening for Cross-Reactivity and Validation of Peptide-Centric CAR-T Cells for Neuroblastoma using MHC Dextramer®

Assessing the HLA-Specificity of CAR-T Cells with MHC I Dextramer® Reagents​

Plasmacytoid Dendritic Cell Line-Based Vaccine Primes and Expands Antitumor T Cells in Melanoma Patients

A TCR-Accepting T-Cell Platform to Profile Tumor-Specific T-Cell Receptors​

Identifying Shared Tumor Epitopes from Endogenous Retroviruses for High-Avidity Cytotoxic TILs using MHC Dextramer®​

Cancer Neoepitopes for Immunotherapy: Strategies for Adoptive T-Cell Therapy​

Identification of Epitopes that Pose as Attractive Targets for Vaccination and Other T-Cell Therapies with Klickmer®

Assessment of the safety and efficacy of a novel vaccine in high-grade glioma patients with Dextramer®

Exploring Neoantigen Cancer Vaccines in Combination with Immune Checkpoint Inhibitors Using MHC Dextramer®​

Dextramer® Reagents Enable TCR Discovery 

Immudex provides a range of ready-to-use, customizable, and peptide-receptive Dextramer® reagents enabling the discovery, characterization, and isolation of TCRs with therapeutic value across different platforms, including in-situ, flow cytometry, NGS, and single-cell multiomics.  

Download TCR Discovery Application Note

TCR Solutions

Immudex offers TCR Solutions providing Soluble TCR Monomers and TCR Dextramer® reagents to enable the quantification of Antigen-Presenting Cells, validation of TCR candidates, and other applications within CAR-T and TCR-T therapy.

Discover TCR Solutions

Want to Hear More About Our Cell Therapy Solutions?

Fill in the form and one of our dedicated specialists will get in touch with you shortly

 

Contact Us